Cargando…
Repurposing Approved Drugs for Sarcopenia Based on Transcriptomics Data in Humans
Sarcopenia, characterized by age-related loss of muscle mass, strength, and decreased physical performance, is a growing public health challenge amid the rapidly ageing population. As there are no approved drugs that target sarcopenia, it has become increasingly urgent to identify promising pharmaco...
Autores principales: | Liang, Shuang, Liu, Danyang, Xiao, Zhengwu, Greenbaum, Jonathan, Shen, Hui, Xiao, Hongmei, Deng, Hongwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145476/ https://www.ncbi.nlm.nih.gov/pubmed/37111364 http://dx.doi.org/10.3390/ph16040607 |
Ejemplares similares
-
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
por: Liu, Dan-Yang, et al.
Publicado: (2021) -
Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016) -
Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021) -
Repurposing approved drugs on the pathway to novel therapies
por: Schein, Catherine H.
Publicado: (2019) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)